No Data
Cosunter Pharmaceutical to Raise 977 Million Yuan From Planned Share Issuance; Shares Down 4%
Fujian Cosunter Pharmaceutical (300436.SZ) plans to raise no more than 0.977 billion yuan through a private placement for the development of Innovative Drugs and other matters.
Fujian Cosunter Pharmaceutical (300436.SZ) disclosed the plan for issuing A-shares to specific targets in 2025, with the company intending to...
Chinese Drug Regulator Accepts Clinical Trial Application of Cosunter Pharmaceutical's Unit for Two Drugs
Fujian Cosunter Pharmaceutical (SZSE:300436) Is Making Moderate Use Of Debt
Fujian Cosunter Pharmaceutical (300436.SZ): The clinical trial application for the Innovative Drugs GST-HG131 combined with GST-HG141 for the treatment of hepatitis B in previously treated patients has been accepted.
On March 17, Gronghui reported that Fujian Cosunter Pharmaceutical (300436.SZ) announced that its Innovative Drugs holding subsidiary, Fujian Guosheng Zhonglin Biotechnology Co., Ltd. (referred to as "Guosheng Zhonglin"), recently received the Acceptance Notice for the clinical trial application from the National Medical Products Administration regarding the hepatitis B treatment Innovative Drug GST-HG131 in conjunction with GST-HG141. This is intended to challenge the clinical cure of hepatitis B in patients with nucleos(t)ide analogues (NUC) treatment history. The aforementioned Phase II clinical study has recently been included in the pilot project for optimizing the review and approval of Innovative Drugs clinical trials, which will effectively shorten the review process for this clinical trial application.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Popularity With Investors Under Threat As Stock Sinks 25%